Financials in USD. Standardized financial statements.
A compact view of how China Shineway Pharmaceutical Group Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.14B | $3.78B | $32.00B | $4.03B | $3.17B | $2.51B | $2.71B | $2.67B | $1.87B | $2.09B |
| Revenue Growth? | -17.0% | -88.2% | +694.0% | +27.1% | +26.3% | -7.5% | +1.5% | +43.3% | -10.6% | 0.0% |
| Cost of Revenue? | $869.21M | $946.29M | $7.95B | $1.03B | $800.05M | $631.57M | $726.50M | $721.98M | $634.12M | $740.30M |
| Gross Profit? | $2.27B | $2.83B | $24.04B | $3.00B | $2.37B | $1.88B | $1.99B | $1.95B | $1.23B | $1.35B |
| Gross Margin? | +72.3% | +75.0% | +75.1% | +74.4% | +74.8% | +74.9% | +73.2% | +73.0% | +66.0% | +64.5% |
| Operating Expenses? | $1.55B | $1.99B | $17.13B | $2.27B | $1.87B | $1.48B | $1.51B | $1.44B | $834.26M | $755.76M |
| Operating Income? | $717.80M | $842.60M | $6.91B | $727.84M | $525.71M | $399.45M | $473.80M | $515.89M | $397.08M | $591.55M |
| EBITDA? | $1.35B | $1.22B | $8.87B | $995.85M | $772.31M | $435.75M | $527.30M | $738.47M | $441.15M | $774.14M |
| Income Before Tax | $1.27B | $1.15B | $1.24B | $935.35M | $708.44M | $373.56M | $644.61M | $695.96M | $571.24M | $728.12M |
| Income Tax Expense | $319.32M | $305.67M | $271.34M | $198.13M | $160.78M | $94.56M | $140.02M | $169.80M | $132.43M | $111.07M |
| Net Income? | $949.95M | $840.05M | $971.65M | $737.22M | $556.67M | $279.00M | $504.59M | $526.16M | $438.82M | $617.05M |
| EPS? | $1.26 | $1.11 | $1.28 | $0.96 | $0.74 | $0.37 | $0.65 | $0.64 | $0.53 | $0.76 |
| Diluted EPS? | $1.26 | $1.11 | $1.28 | $0.96 | $0.74 | $0.37 | $0.65 | $0.64 | $0.53 | $0.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality